Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.18

€0.18

1.140%
0.002
1.140%
€1.50
 
20.06.24 / Tradegate WKN: A2PSPW / Name: Innocan Pharma Corp. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for Innocan Pharma Corp.

sharewise wants to provide you with the best news and tools for Innocan Pharma Corp., so we directly link to the best financial data sources.

News

Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million : https://www.irw-press.at/prcom/images/messages/2024/75707/Innocan_052724_ENPRcom.001.png
Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million

Herzliya, Israel and Calgary, Alberta - May 27, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company

Innocan Pharma to participate in the White Label World Expo on February 27-28th, 2024: https://www.irw-press.at/prcom/images/messages/2024/73634/InnocanPharma_EN_PRcom.001.jpeg
Innocan Pharma to participate in the White Label World Expo on February 27-28th, 2024

Herzliya, Israel and Calgary, Alberta - (February 20, 2024) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), is pleased to announce that CEO Iris

Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs
Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs

Herzliya, Israel and Calgary, Alberta - June 11, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and

FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain
FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain

The regulatory approval process with the U.S. Food and Drug Administration has commenced for Innocan’s LPT-CBD release technology, marking a key step in the advancement of non-opioid pain

Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey

Herzliya, Israel and Calgary, Alberta - May 09, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD

Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M

Herzliya, Israel and Calgary, Alberta – April 1, 2024 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company

Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.
Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.

Herzliya, Israel and Calgary, Alberta - March 25, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug

Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million

 

NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

 

HERZLIYA, Israel and CALGARY, Alberta – March 15, 2024 – Innocan Pharma Corporation (the “

Innocan Pharma’s LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study
Innocan Pharma’s LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study

Innocan Announces Notice of Intention to Complete a Private Placement of Units

 

Herzliya, Israel and Calgary, Alberta – March 5, 2024 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4)

Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits
Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits

Herzliya, Israel and Calgary, Alberta – February 26, 2023 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and

Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights
Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights

Herzliya, Israel and Calgary, Alberta - (February 13, 2024) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), is pleased to provide the

Innocan Pharma to provide a corporate update via Zoom livestream on February 12, 2024, at 4:00pm EST
Innocan Pharma to provide a corporate update via Zoom livestream on February 12, 2024, at 4:00pm EST

Herzliya, Israel and Calgary, Alberta - (February 5, 2024) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that it will provide a